Jan Dürig

6PUBLICATIONS
39CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.

Henriette Huber, Eugen Tausch, Christof Schneider

|Dec 05, 2022
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.

Olivier Hermine, Linmiao Jiang, Jan Walewski

|Aug 26, 2022
Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.

Jan Dürig, Jens Uhlig, Anke Gerhardt

|May 23, 2022
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.

Mattia D'Agostino, David A Cairns, Juan José Lahuerta

|Apr 10, 2018
Light chain monoclonal gammopathy of undetermined significance is characterized by a high disappearance rate and low risk of progression on longitudinal analysis.

Benedikt W Pelzer, Marina Arendt, Susanne Moebus

Pageof 1

Frequent Collaborators

2 joint publications

Hartmut Goldschmidt

2 joint publications

Elias K Mai

1 joint publications

Mattia D'Agostino

1 joint publications

David A Cairns